The CARD study results were reported at the 2019 ESMO meeting and simultaneously published in the NEJM. CARD investigated the efficacy and safety of cabazitaxel as compared with an androgen-receptor-signaling inhibitor ( ARSI; abiraterone or enzalutamide), in patients with mCRPC who were previously treated with docetaxel and had progressed within 12 months while receiving the alternative inhibitor (abi or enza).